Figure 2
Figure 2. Assessment of the mitochondrial membrane potential (Áøm) in HBL-2 and Granta (MCL). (A) HBL-2 and Granta cells were incubated with AT-101 from 100 nM to 10 μM for 24 hours. (B) Granta cells were incubated with AT-101 (AT, 2 μM) or carfilzomib (C, 6 or 10 nM) or both for 24 hours. The combination of AT-101 plus C at 6 nM was statistically significant compared to any of the single groups and controls (P ≤ .004). (C) HBL-2 cells were incubated with AT-101 (AT, 1 μM), carfilzomib (C, 6 nM) or for 24 hours. Again, the combination of AT-101 plus C was statistically significant compared to any of the single groups and controls (P ≤ .009). Error bars represent SD.

Assessment of the mitochondrial membrane potential (Áøm) in HBL-2 and Granta (MCL). (A) HBL-2 and Granta cells were incubated with AT-101 from 100 nM to 10 μM for 24 hours. (B) Granta cells were incubated with AT-101 (AT, 2 μM) or carfilzomib (C, 6 or 10 nM) or both for 24 hours. The combination of AT-101 plus C at 6 nM was statistically significant compared to any of the single groups and controls (P ≤ .004). (C) HBL-2 cells were incubated with AT-101 (AT, 1 μM), carfilzomib (C, 6 nM) or for 24 hours. Again, the combination of AT-101 plus C was statistically significant compared to any of the single groups and controls (P ≤ .009). Error bars represent SD.

Close Modal

or Create an Account

Close Modal
Close Modal